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Summary There is clear evidence that BCG protects against leprosy, but cross-
immunity with environmental mycobacteria can interfere with vaccination
protection. Some have cast doubts whether BCG vaccination can offer a significant
impact against leprosy in the Brazilian Amazon, which is an endemic area for leprosy
and with a high prevalence of environmental mycobacteria. This study was designed
to estimate the vaccine effectiveness of neonatal BCG against leprosy in Amazon
region, in Brazil. This is a cohort study nested in a randomized community trial. The
study had two main results. First, neonatal BCG vaccination in Brazilian Amazon
elicited protection of 74% (95% CI 57–86) against all forms of leprosy cases.
Second, the highest protection was observed for multibacillary cases, 93% (95% CI
71–98). It is concluded that the study provides evidence that neonatal BCG may have
an important and overlooked impact on the occurrence and transmission of leprosy,
maybe even more in the future when the cohort which received a high coverage of
BCG reaches the age of high incidence of leprosy.
Introduction
There is clear evidence that BCG protects against leprosy, but the level of protection has
ranged from 20% to 90% in different studies.1,2 One hypothesis to explain this variation is
cross-immunity with environmental mycobacteria (EM).3,4
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Brazil is a large country and has the second greatest number of cases of leprosy in the world
detected each year.5 The Brazilian leprosy control programme advocates the identification and
treatment of all cases to control the disease, and as a complementary measure the BCG
vaccination among household contacts of leprosy cases.6 The disease has an uneven
geographical distribution in the country, and the Brazilian Amazon region is an important
endemic area where a high prevalence of EM is assumed.7 Because of the hypothesis that
infection with EM can interfere in the protection elicited by BCG 4, some have cast doubts on
whether BCG vaccination can offer a significant impact against leprosy8 or against
tuberculosis9 in the Brazilian Amazon. Indeed, in Manaus, the largest urban centre in Brazilian
Amazon, the vaccination coverage among household contacts of leprosy cases is low.
The present study took opportunity of an ongoing community trial of BCG vaccination of
school children in a population with high coverage of neonatal BCG (REVAC-BCG trial) to
estimate the vaccine effectiveness of neonatal BCG against leprosy in Amazon region in Brazil.
Materials and methods
STUDY DESIGN
This is a cohort study nested in one of the study sites of the REVAC-BCG community trial.
This trial aims to evaluate the vaccine effectiveness of BCG given to schoolchildren against
tuberculosis and leprosy and has two study sites, the cities of Salvador and Manaus. This
cohort study was conducted in Manaus, where the trial was implemented in 1998. Details of
the trial have been described elsewhere.10,11 Briefly, it was a cluster randomized without
placebo community trial. The study population of this cohort study was followed up in two
periods and had thus two components (see Figure 1). First, from 1989 to 1997 (before
implementation of the trial) corresponded to a historical cohort study involving the trial
population from both control and intervention trial arms. Second, from 1999 to August 2002,
during the trial follow-up, corresponded to a prospective cohort study involving only the trial
population in the control arm, as this study is concerned with the neonatal dose and most
individuals of the intervention arm received two doses.
STUDY SITE
This cohort study was conducted in the city of Manaus, with about 1,500,000 inhabitants
(1999 census) on the banks of the Negro River, Brazilian Amazon region, with a tropical
Figure 1. Historical and prospective follow-up periods.
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climate and high humidity, close to the equator line (latitude 38 70 south, longitude 608
1300 west). Differently from the other trial site (Salvador), Manaus has a higher
incidence of leprosy with a new case detection rate (NCDR) of about 5–6 per 10,000
every year.
STUDY POPULATION
The cohort participants consisted of the schoolchildren recruited into the trial, who were born
between 1983 and 1991 (aged 7–14 years at recruitment into the trial), and residing in
Manaus. The trial, and this study, was restricted to children attending state schools. Only
children with no BCG scar or one scar entered in this cohort study (n ¼ 112,744 in total study
population; n ¼ 60,458 in control group). Identification and vaccination data recorded in the
REVAC-BCG trial database were used in this cohort study.
VACCINATION ASCERTAINMENT
The presence of a scar compatible with BCG vaccination was used as a surrogate of BCG
neonatal vaccination in the REVAC-BCG trial and in this cohort study. BCG scar reading was
performed during the recruitment phase of the trial in 1998 (Manaus) by trained health
workers who visited the schools, and data entered in the trial database. Validation of the scar
as a marker of BCG vaccination in the trial population in Manaus is published elsewhere.12 In
summary, BCG scar reading had a sensitivity between 94% and 98%, depending on age
group, when the gold standard was the agreement between parental information about past
vaccination and vaccination card.
CASE ASCERTAINMENT AND CLASSIFICATION
Data on all cases regarding identification data, clinical form, and date of diagnosis of all
leprosy cases in the city of Manaus are routinely entered in a computerized database of the
local control programme. In this cohort study, leprosy cases diagnosed between 1989 and
1997 (historical cohort), and between 1999 and August 2002 (prospective cohort), in
children eligible to the trial population, were ascertained from the local leprosy control
programme. All cases reported as indeterminate, tuberculoid and BT (bordeline
tuberculoid) were classified as paucibacillary (PB) cases; and LL (lepromatous
lepromatous), BB (borderline borderline), BL (borderline lepromatous) as multibacillary
(MB). Cases reported as dimorphous were classified as multibacillary, but those with
negative baciloscopy and who received PB multi-drug therapy (MDT) regime were
classified as paucibacillary.
CASE LINKAGE
The leprosy cases recorded in the database of the local leprosy control programme were
linked to the records in the REVAC-BCG trial database. The matching between cases and
trial study population was done based on variables present in both databases: subject’s name,
date of birth, sex, and mother’s name.
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INCIDENCE OF LEPROSY AND TUBERCULOSIS FOR GEOGRAPHICAL AREA
The city of Manaus is divided in 56 administrative areas (districts), and two categorical
variables were created indicating if the schools were the students attended in 1998 were
located in districts with incidence of leprosy (NCDR) and tuberculosis below or above to the
incidence of the city in 1996 as a whole. These variables were taken as a proxy of the baseline
risk and socio-economic status (as leprosy and tuberculosis are diseases related to poverty) of
the trial study population and in the prospective cohort. However, chosen was made to not use
these variables in the analysis of the historical cohort because they may not express the
baseline risk during the longer period before the trial in the historical cohort, which included
period until 6–7 years before 1996.
STATISTICAL PROCEDURES
Incidence of leprosy per 10,000 (NCDR) was estimated in children separately by BCG scar,
current age, sex, and leprosy classification. Confidence intervals (95% CI) of crude rates and
rate ratios were estimated according to an approximation to the Poisson log-likelihood for the
log rate parameter.13 If the number of cases was smaller than 30, the confidence intervals of
rates were estimated according to exact confidence limits for a Poisson-distributed variable.14
Interaction was done using the log likelihood ratio test.13 Age was categorized in groups and
was treated as time-varying variable, expressed as current age (age during the cohort follow-
up) through expansion of the data-set in time scales.13 BCG vaccine effectiveness was
estimated as (1–rate ratio) £ 100. Adjusted rate ratios for current age, sex, year of birth and
incidence of leprosy and tuberculosis for geographical areas were obtained by using standard
Poisson regression. All the statistical analysis was done using STATA version 7.015.
Results
In the historical cohort study, 128 leprosy cases diagnosed between 1989 and 1997 in Manaus
were linked to the trial study population. One hundred and seven (107) cases were classified
as paucibacillary cases (21 indeterminate, 78 tuberculoid, three dimorphous, five BT) and 21
as multibacillary cases (three LL, one BL, 17 dimorphous). The three reported dimorphous
cases classified as paucibacillary had negative baciloscopy and received the paucibacillary
MDT regime.
In the prospective cohort study, 53 leprosy cases diagnosed between 1999 and August
2002 were linked to the trial study population. Forty-three (43) were classified as
paucibacillary cases (23 tuberculoid, nine indeterminate, 10 BT, one just reported as
paucibacillary case) and 10 cases as multibacillary (one BB, four dimorphous, three BL, two
LL). All these four dimorphous cases had positive baciloscopy and were treated with
multibacillary MDT regime.
Among cases in the historical cohort, 35 (27·3%) had no BCG scar and 93 (72·7%) had one
scar; 75 (58·6%) were females and 53 (41·4%) males. In the prospective cohort, 22 (41·5%)
had no BCG scar and 31 (58·5%) had one scar; 24 (45·3%) were females and 29 (54·7%)
males. These figures compare with 84·0% with BCG scar and 51·3% of females in the total
trial population (84·8% and 51·4% in control group, respectively).
For the whole trial population, the prevalence of BCG scar was higher for those born
in recent years: 79·8%, 85·6% and 88·9%, for those born in 1983–1986, 1987–1988, and
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1989–1991, respectively. For the control group these figures were 80·9%, 86·3%, 89·5%,
respectively.
Table 1 shows the crude rates according to sex, current age and incidence of leprosy and
tuberculosis in geographical areas in 1998. In historical cohort, females and older individuals
had higher rates than males (rate of 1·51 versus 1.13) and younger people (rate of 3·22 versus
0.28). In prospective cohort, males presented higher rates than females (rate of 2·93 versus
2.30) and older individuals yet had higher rates than younger (rate of 2·93 versus 1.91). In the
prospective cohort, rates of leprosy were higher among those attending schools in 1998
located in areas with higher rates of leprosy and tuberculosis (but without statistical
significance).
In the historical cohort, the rate per 10,000 for multibacillary cases were 0·22 (21/968,369
person years; 95% CI: 0·17–0·37) and for paucibacillary cases was 1·04 (107/968,369; 95%
CI: 0·86–1·27). In the prospective cohort, the rates were 0·49 (10 cases/203,507 person years;
95% CI: 0·26–0·91) and 2·11 (43 cases/203,507; 95% CI: 1·57–2·84), respectively (data not
shown).
Table 2 shows the crude and adjusted (current age, sex and calendar year of birth) rate
ratios for leprosy in historical cohort, according to presence of BCG scar and case
classification. The adjusted estimates of vaccine effectiveness were: 41% (95% CI:
12—60%) for all leprosy cases, 77% (95% CI: 45–90%) for multibacillary cases, 26% (95%
CI: –16–53%) for all paucibacillary cases, and no statistically significant protection for
paucibacillary cases excluding intermediate and for indeterminate cases. Except for
multibacillary cases, the difference between crude and adjusted rate ratios varied between
Table 1. Rates of leprosy per 10,000 separately by sex, current age and incidence of leprosy and tuberculosis in
geographical areas (prospective cohort)
Study variable No cases Person-years Rate per 10,000 Rate ratio (CI 95%)
Historical cohort (n ¼ 128)
Sex
Female 75 497,950 1·51 1
Male 53 470,420 1·13 0·75 (0·53–1·06)
Current age (years old)
0–5 10 360,490 0·28 1
6–9 77 480,610 1·60 5·78 (3·00–11·16)
10–15 41 127,270 3·22 11·61 (5·82–23·18)
Prospective cohort (n ¼ 53)
Sex
Female 24 104,530 2·30 1
Male 29 98,977 2·93 1·28 (0·74–2·19)
Current age (years old)
7–9 4 20,990 1·91 1
10–14 25 100,520 2·49 1·31 (0·45–3·75)
15–18 24 82,000 2·93 1·54 (0·53–4·43)
Incidence of tuberculosis in before follow-up (1998)a
‘Low’ 34 143,471 2·37 1
‘High’ 18 56,423 3·19 1·35 (0·72–2·45)
Incidence of leprosy before follow-up (1998)b
‘Low’ 21 99,011 2·12 1
‘High’ 32 102,398 3·13 1·47 (0·82–2·69)
a Excluding 1074 individuals and one leprosy case with missing data about incidence of tuberculosis.
b Excluding 623 individuals (without leprosy case) with missing data about incidence of leprosy.
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13% and 18%, indicating confounding effect (taking the threshold of 10% to define
confounding), attributed to the association of year of birth with presence of BCG scar and
leprosy rates. There was no statistically significant interaction between presence of BCG scar
and current age, year of birth and sex (data not shown).
Table 3 shows the crude and adjusted rate ratios for leprosy in prospective cohort,
according to presence of BCG scar, and case classification. The adjusted estimates of vaccine
Table 2. Rate ratios for leprosy according to presence of BCG scar, separately by clinical forms, in historical cohort
Neonatal BCG scar
Study variable One No Rate ratio (95% CI)
All cases (n ¼ 128)
Cases (rate per 10,000)a 93 (1·15) 35 (2·23) Crude estimate 0·51 (0·35–0·76)
Poisson regressionb 0·59 (0·40 to 0·88)
Multibacillary cases (n ¼ 21)
Cases (rate per 10,000) 11 (0·13) 10 (0·64) Crude estimate 0·21 (0·09–0·50)
Poisson regressionb 0·23 (0·10–0·55)
Paucibacillary cases (n ¼ 107) (including indeterminate)
Cases (rate per 10,000) 82 (1·01) 25 (1·59) Crude estimate 0·63 (0·41–0·99)
Poisson regressionb 0·74 (0·47–1·16)
Paucibacillary cases (n ¼ 86) (excluding indeterminate)
Cases (rate per 10,000) 65 (0·80) 21 (1·34) Crude estimate 0·60 (0·37–0·98)
Poisson regressionb 0·69 (0·42–1·13)
Indeterminate cases (n ¼ 21)
Cases (rate per 10,000) 17 (0·21) 4 (0·26) Crude estimate 0·82 (0·28–2·40)
Poisson regression2 1·01 (0·34–3·02)
a Total person year of 811,554 and 156,815, for vaccinated and unvaccinated, respectively.
b Estimate controlled for current age, sex and year of birth (categorical variables).
Table 3. Rate ratios for leprosy according to presence of BCG scar, by clinical forms, in prospective cohort
Neonatal BCG scar
Study variable One No Rate ratio (95% CI)
All cases (n ¼ 53)
Cases (rate per 10,000)a 31 (1·80) 22 (7·10) Crude estimate 0·25 (0·15–0·44)
Poisson regressionb 0·25 (0·14–0·43)
Multibacillary cases (n ¼ 10)
Cases (rate per 10,000) 3 (0·17) 7 (2·26) Crude estimate 0·08 (0·02–0·30)
Poisson regressionb 0·07 (0·02–0·29)
Paucibacillary cases (n ¼ 43) (including indeterminate)
Cases (rate per 10,000) 28 (1·62) 15 (4·84) Crude estimate 0·34 (0·18–0·63)
Poisson regressionb 0·33 (0·17–0·62)
Paucibacillary cases (n ¼ 34) (excluding indeterminate)
Cases (rate per 10,000) 21 (1·22) 21 (4·19) Crude estimate 0·29 (0·15–0·60)
Poisson regressionb 0·28 (0·14–0·56)
Indeterminate cases (n ¼ 9)
Cases (rate per 10,000) 7 (0·41) 2 (0·65) Crude estimate 0·63 (0·13–3·03)
Poisson regressionb 0·69 (0·14–3·35)
a Total person year of 172,505 and 31,003, for vaccinated and unvaccinated, respectively.
b Estimate controlled for current age, sex, year of birth and incidence of leprosy and tuberculosis in geographical
areas before the trial follow-up (categorical variables).
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effectiveness were 75% (95% CI: 57–86%) for all leprosy cases, 93% (95% CI: 71–98%) for
multibacillary cases, 67% (95% CI: 38–83%) for all paucibacillary cases, 72% (95% CI:
44–86%) for paucibacillary cases excluding intermediate cases, and no significant protection
for indeterminate cases. Differently from the historical cohort, there were slight differences
between crude and adjusted rate ratios, indicating no confounding effect with the study
variables. Similarly to historical cohort, there was no statistically significant interaction
between presence of BCG scar and current age, year of birth and sex.
Discussion
The study had three main results. First, neonatal BCG vaccination in Manaus (Brazilian
Amazon) elicited protection between 41% and 74% against all forms of leprosy cases.
Secondly, when the categories were considered separately, the highest protection was
observed for multibacillary cases, with little or no protection for indeterminate cases. Third,
this protection did not change with current age.
This study consisted of two cohorts, one historical and another prospective, which might
well have brought about different results, and hence were analysed separately. First, in the
prospective cohort, individuals were older than in the historical cohort. In Manaus, the rates
for leprosy increase with age and become more stable among adults. Therefore, the leprosy
rates were more similar across age groups in the prospective cohort and hence less associated
with year of birth. This can explain why year of birth, which was also associated with
presence of BCG scar in both cohorts, was a confounder in the historical cohort (because was
also associated with leprosy rates) but not in the prospective study (because was not
associated with leprosy rates).
Second, individuals were included into the study population when they enrolled into
schools, and in the historical cohort, by the nature of the design, enrolment was after case
detection. This is known as ‘late entry’ and can introduce selection bias.13 Individuals who
got disease (leprosy cases) might be less likely to be enrolled into schools because of the
disease and hence more likely to be excluded from the cohort. The estimate of vaccine
protection would be biased if the proportion of cases enrolled into school among those
vaccinated were different from those unvaccinated. This might well happen, for instance, if
BCG vaccination caused shifts in clinical forms, leading to milder cases, as suggested in
previous studies.16,17 Mild cases could be more likely to be enrolled into schools than severe
cases. Consistently with this possibility, in the historical cohort the proportion of
paucibacillary cases linked in the trial population (22%) was slightly higher than the
proportion of multibacillary cases linked (17%) (data not shown), although this was not
statistically significant. A differential enrolment would lead to a differential loss of
unvaccinated cases (as these would be more likely to be multibacillary), and therefore to an
underestimation of vaccine protection. This bias would not be present in the prospective
cohort, as the leprosy cases were traced after the cohort was established, with no differential
loss of vaccinated cases. This again is consistent with the protective effect estimated in the
historical cohort being lower than the protective effect estimated in the prospective cohort. If
this is the explanation for the differences in protective effect estimated in the two cohorts,
then the unbiased, correct measure, is the higher protection estimated in the prospective
cohort.
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Third, this is an observational study, and these estimates of effect measure are valid
as long as confounding can be controlled for. One important potential confounder is
socio-economic status, related to vaccine uptake as well as risk of leprosy. Incidence of
leprosy and tuberculosis before the follow-up in geographical areas where schools were
located were used as proxy for baseline risk and socio-economic status in prospective cohort.
Therefore, the estimates obtained from prospective cohort should be considered less likely to
be distorted by confounding effect.
If one accepts that BCG shifts cases from the multibacillary to the paucibacilary end of
the leprosy spectrum, one could postulate scenarios where BCG could increase the risk of
paucibacillary cases. This was observed for indeterminate cases,17,18 as well as a higher rate
of leprosy among those vaccinated (all with tuberculoid and indeterminate forms) than among
those unvaccinated (Bechelli and Quagkiato, 1953 and 1956; cited in 19). This shift would
lead to an underestimated vaccine protection for paucibacillary forms, as the incidence would
increase with vaccination. This hypothesis is consistent with results in both cohorts in our
study, in which the lowest vaccine effect was observed for paucibacillary cases, and the
highest value was for multibacillary cases.
There may be an interaction in immune protection among different Mycobacteria
species.4,20 It has been suggested that the variation in BCG protection against leprosy (as well
as against tuberculosis) could be caused by the presence of infection by environmental
mycobacteria (EM). But studies so far have failed to disentangle the intriguing interaction
between BCG and EM, which remains the subject of lively debate. For instance, the study
population of the Malawi trial had a high prevalence of skin reactors for EM antigens, and
prior sensitisation to fast growers EM led to reduced risk of both leprosy and tuberculosis,20
even though BCG still protected against leprosy, but not against tuberculosis.
Most endemic areas of leprosy in Brazil are located in tropical or equatorial regions, such
as Manaus, and there is some evidence that Manaus has a high prevalence of EM. First, the
city is located in area with high humidity and temperature, factors favouring the growth of
EM.21 Second, a recent survey demonstrated a prevalence of infection for Mycobacterium
avium of nearly 60% among the REVAC-BCG trial study population.22 Third, isolates of EM
have been found to be more common in sputum from tuberculosis patients in Manaus than in
other areas in Brazil.23 However, the results of our study do not support the idea that the
protection offered by neonatal BCG vaccination against leprosy is substantially reduced
because of the high prevalence of EM in Manaus. The findings of this study are consistent
with previous studies in Brazil, in which shown that BCG vaccination confers protection
against leprosy.2,24,25
It is worth noting that neonatal BCG in Brazil has reached coverage rates of 90% in the
late 1990s (this was reflected in our data by the higher prevalence of BCG scar among those
born in recent years). Therefore, most Brazilians up to the age of 15 will have at least some
protection against leprosy. Perhaps more important, we found protection against the
multibacillary cases, suggesting BCG must have an impact on transmission of leprosy. This
impact would also depend on the proportion of the multibacillary cases in the whole
population that come from schoolchildren, the vaccine coverage rate, and for how long
protection lasts. In the literature, there is evidence that BCG elicits protection against
multibacillary cases as well as paucibacillary.16,26,27
The finding that this protection did not change with age suggests that the protection lasted
for 10–15 years after vaccination. It was recently reported that BCG protection against
tuberculosis can last for 50–60 years after vaccination.28 If BCG also elicits a long-lasting
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protection against leprosy, neonatal BCG, which is given routinely to prevent tuberculosis,
may have an important and overlooked impact on the occurrence and transmission of leprosy
in the future, when the cohort which received a high coverage of BCG reaches the age of high
incidence of leprosy and replaces the previous generation. However, this finding must be
interpreted carefully because of the low power to assess interaction.
In conclusion, this study provides evidence that neonatal BCG may have an important and
overlooked impact on the occurrence and transmission of leprosy, perhaps even more in the
future when the cohort which received a high coverage of BCG reaches the age of high
incidence of leprosy.
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